The history of steroidal intravenous anaesthesia is traced. Althesin was used as an induction agent in 60 elective minor gynaecological procedures requiring general anaesthesia, followed by nitrous oxide/oxygen maintenance anaesthesia.
INTRODUCTION
The anaesthetic properties of steroids were described more than 30 years ago (Selye 1941) .
Compared to the barbiturates, steroidal anaesthetics have two advantage": a greater therapeutic ratio (greater margin of safety) and a more clear-headed recovery (recovery not affected by redistribution because of progressive destruction by the liver). The one consistent disadvantage is the insolubility in water. Hitherto attempts at overcoming this disadvantage resulted in clinical complications (thrombophlebitis and venous thrombosis).
Hydroxydione was introduced in the 1950s (Murphy, Gaudagni and Debon 1955 , Lerman 1956 , Taylor and Shearer 1956 , Galley and Rooms 1956 ). This steroid anaesthetic was clinically unacceptable because of the high incidence of pain on injection and of postanaesthetic thrombophlebitis besides the long delay in onset of action.
The search continued for a steroid anaesthetic drug with the following properties: water-solubility, wide safety margin, pleasant induction and recovery from anaesthesia, freedom from vascular irritation, no paraesthesia production and rapid induction with the high potency of barbiturates.
The latest steroidal anaesthetic, CT 1341 (now known as Althesin) seems to have surmounted most of the problems. This agent is a combination of two steroids: Alphaxalone (30 ( -hydroxy -50( -pregnane -11, 20 dione) (21-acetoxy-30(hydroxy-50(-pregnane-11, 20 dione) dissolved in in 20 per cent Cremophor EL (polyoxyethylated castor oil) made isotonic with blood with sodium chloride (Tahle I).
Alphaxalone is the principal potent anaesthetic (dissolved in 20 per cent Cremophor EL) and Alphadolone acetate (half as potent) is added mainly to enhance the solubility. Being a combination of two steroids in different concen-trations, it is more convenient to work out the dosage of Althesin on a volume (millilitres or microlitres) basis per kilogram of body weight. This paper reports the clinical experiences with the use of Althesin as an inducticn agent in 60 cases presenting for elective, minor gynaecological procedures under general anaesthesia.
}IATERIAL AND }IETHODS
Althesin (eT 134]) was used as an intravenous induction agent in 60 fit patients presenting for elective, minor gynaecological procedures (diagnostic dilatation and curettage, tubal insufflation, cervical cautery) under general anaesthesia. Mean age was 34·2 years (range: ] 9-67 years) and mean body weight 51·3 kg (range: 33·3-71·2 kg). All patients received intramuscular pethidine and promethazine for pre-anaesthetic medication }-1 hour preinduction.
The Althesin induction dose was calculated on a 0 ·05 ml/kg body weight basis. The intravenous induction injection (via a 21 s.w.g. needle) was administered over 15 seconds. The time of injection to unconsciousness was noted. Following induction, maintenance anaesthesia was with nitrous oxide/oxygen (5·51/2·5 I) on the Magill semi-closed circuit using an oropharyngeal airway and mask with jaw support. During induction any abnormal muscle movement, coughing, hiccoughing, or laryngospasm was noted and the pupils were observed. Systolic blood pressure, pulse rate (by palpation) and respiratory rate were noted before induction and at two, four, six, ei!!ht and 10 minutes after induction. During the procedure any reaction (movement) to painful stimuli was noted.
At the conclusion of the procedure the patients were taken to the recovery room. Response to simple command (" open your eye" ") was assessed at two, four, 5ix, eight and 10 minute intervals. The time of reorientation to name and place was noted. During the recovery phase any restlessness, nausea and/or vomiting, and any emotional display, were recorded. The next morning the patient was interviewed and the injected vein examined for t hrom bophle bit is.
RESULTS
The mean duration of the pro:edures was 10·2 minutes (range: 8-16·4 minutes).
The mean interval from induction injection to loss of consciousness was 14 seconds (range: 8-26 seconds).
At induction the incidence of inductionassociated phenomena is shown in Table 2 . Pulse rate rose in all cases. The mean values at two, four, six, eight and ]0 minutes and the pre-induction value are shown graphically in Figure 1 . The mean maximum rise was 26/min (range: 10-34/min) and occurred in four minutes. pre-induction values. The mean maximum fall occurred within two minutes. Five (8·3 per cent) patients showed Cl. rise of more than 10 mm Hg (range: 10-22 mm Hg); the maximum rise was within four minutes. The remaining 11 patients showed a fall or rise of less than 10 mm Hg (range: 2-10 mm Hg). > 10 mm Hg-44 showed a fall, five showed a rise. Eleven patients showed a rise or fall of < 10 mm Hg.
Respiratory Rate Changes (Figure 3 ) Forty-seven patients (78·3 per cent) showed a rise in respiratory rate (range: 2-10jmin); the mean maximum rise occurred in four minutes. Thirteen patients (21·7 per cent) showed a fall (range: 3-9jmin); the maximum fall was within two minutes. During the procedure 13 (25 per cent) patients of 52 who underwent D. and C.'s reacted by movement to painful stimulus (cervical dilatation). Sixteen (72·2 per cent) of 22 earlier cases who were given only Althesin (not followed with N20j02) reacted similarly, and because of the high incidence of poor analgesia the 60 patients studied in this paper were managed with Althesin followed by N20j02.
Recovery (Table 3 ) was smooth and uncomplicated in 50 cases (83·3 per cent). Of the 60 patients, 42 (70 per cent) demonstrated a pleasantly euphoric emergence. Three (5 per cent) showed tearfully emotional emergence, while the remaining 15 showed no undue emotional change. Nausea occurred in four (6·7 per cent), restlessness in three (5 per cent). .... _ .................. -....... . Response to commands (" open your eyes ") at two, four, six, eight and 10 minutes is shown in Figure 4 . By 10 minutes all patients responded to simple command. The mean time of reorientation to name and place was 16·2 minutes (range: 13-22 minutes).
Only 10 patients were interviewed the next day (50 had been discharged the same day) personally. All expressed complete satisfaction with the anaesthesia and there was no evidence of thrombophlebitis or of hallucinations or dreams in any case.
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DISCUSSION
The clinical experiences in this study are, generally, similar to those shown bv most others investigating the use of Althesin (CT 1341).
Loss of consciousness was within one arm-brain circulation time (Clarke, Dundee and Carson 1972) . A fall in blood pressure, rise in pulse and respiratory rates were also shown (Savege et al. 1971 , Campbell et al. 1971 , Savege et al. 1972 . Others (Savege et al. 1972) have shown that cardiac output is maintained or raised with Althesin. Recovery is rapid, as previously shown in animal and human studie; (Child et al. 1971 , Campbell et al. 1971 , Clarke et al. 1971 , Savege et al. 1971 with minimal hanfover effects.
The patients found the anaesthesia pleascmt, as shown by the high incidence of euphoria ( Campbell et al. 1971) . The poor analgesic effect has been shown to be similar tc that (ant analgesic effect) of thiopentone by ~Iorgan, Whitwam and Page (1973) . Althesin (CT 1341) has a characteristic odour (similar to that of castor oil) and is slippery to touch. The ampoule contains a slightly viscous liquid which should not be shaken because frothing ensues and the bubbles are very difficult to get rid of. The manufacturers recommend that the ampoule:' should be stored at room temperature. Storage in a refrigerator is warned against because the steroids tend to precipitate out and are then difficult to resolubilize.
In this initial expenence with a relatively small number of patients no case showed an anaphylactoid reaction.
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